|
|
Article: NitroMed's BiDil Approved For Heart Failure In Black Patients.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
The FDA approved BiDil, NitroMed Inc.'s heart failure treatment for black patients, though curiously the company was tight-lipped on news of its first approval and trading in the stock was held Friday.
"It's leaving many of us on Wall Street scratching our heads," said David Moskowitz, an analyst at Friedman, Billings, Ramsey & Co., adding that "situations like this cause investors to speculate."
NitroMed executives declined to comment to BioWorld Today and other media outlets, and earlier that morning they canceled a television interview with the CNBC cable outlet. Moskowitz told BioWorld Today that speculation arising from ...